138 related articles for article (PubMed ID: 31475679)
1. Prostate biopsy evolution and the need for repeat biopsy - The role of image and new prostate cancer biomarkers.
Gil-Sousa D; Oliveira-Reis D; Tavares C; Teves F; Osório L; Gomes M; Soares J; Fraga A
Arch Esp Urol; 2019 Sep; 72(7):677-689. PubMed ID: 31475679
[TBL] [Abstract][Full Text] [Related]
2. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S
BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer gene 3 (PCA3) is of additional predictive value in patients with PI-RADS grade III (intermediate) lesions in the MR-guided re-biopsy setting for prostate cancer.
Kaufmann S; Bedke J; Gatidis S; Hennenlotter J; Kramer U; Notohamiprodjo M; Nikolaou K; Stenzl A; Kruck S
World J Urol; 2016 Apr; 34(4):509-15. PubMed ID: 26267808
[TBL] [Abstract][Full Text] [Related]
4. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.
Brown LC; Ahmed HU; Faria R; El-Shater Bosaily A; Gabe R; Kaplan RS; Parmar M; Collaco-Moraes Y; Ward K; Hindley RG; Freeman A; Kirkham A; Oldroyd R; Parker C; Bott S; Burns-Cox N; Dudderidge T; Ghei M; Henderson A; Persad R; Rosario DJ; Shergill I; Winkler M; Soares M; Spackman E; Sculpher M; Emberton M
Health Technol Assess; 2018 Jul; 22(39):1-176. PubMed ID: 30040065
[TBL] [Abstract][Full Text] [Related]
5. Magnetic resonance imaging in prostate cancer detection and management: a systematic review.
Monni F; Fontanella P; Grasso A; Wiklund P; Ou YC; Randazzo M; Rocco B; Montanari E; Bianchi G
Minerva Urol Nefrol; 2017 Dec; 69(6):567-578. PubMed ID: 28488844
[TBL] [Abstract][Full Text] [Related]
6. The roles of multiparametric magnetic resonance imaging, PCA3 and prostate health index-which is the best predictor of prostate cancer after a negative biopsy?
Porpiglia F; Russo F; Manfredi M; Mele F; Fiori C; Bollito E; Papotti M; Molineris I; Passera R; Regge D
J Urol; 2014 Jul; 192(1):60-6. PubMed ID: 24518780
[TBL] [Abstract][Full Text] [Related]
7. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study.
van der Leest M; Cornel E; Israël B; Hendriks R; Padhani AR; Hoogenboom M; Zamecnik P; Bakker D; Setiasti AY; Veltman J; van den Hout H; van der Lelij H; van Oort I; Klaver S; Debruyne F; Sedelaar M; Hannink G; Rovers M; Hulsbergen-van de Kaa C; Barentsz JO
Eur Urol; 2019 Apr; 75(4):570-578. PubMed ID: 30477981
[TBL] [Abstract][Full Text] [Related]
8. Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR.
Rosenkrantz AB; Verma S; Choyke P; Eberhardt SC; Eggener SE; Gaitonde K; Haider MA; Margolis DJ; Marks LS; Pinto P; Sonn GA; Taneja SS
J Urol; 2016 Dec; 196(6):1613-1618. PubMed ID: 27320841
[TBL] [Abstract][Full Text] [Related]
9. An update on prostate biopsy in the era of magnetic resonance imaging.
Cicione A; De Nunzio C; Manno S; Damiano R; Posti A; Lima E; Tubaro A; Balloni F
Minerva Urol Nefrol; 2018 Jun; 70(3):264-274. PubMed ID: 29595039
[TBL] [Abstract][Full Text] [Related]
10. In-parallel comparative evaluation between multiparametric magnetic resonance imaging, prostate cancer antigen 3 and the prostate health index in predicting pathologically confirmed significant prostate cancer in men eligible for active surveillance.
Porpiglia F; Cantiello F; De Luca S; Manfredi M; Veltri A; Russo F; Sottile A; Damiano R
BJU Int; 2016 Oct; 118(4):527-34. PubMed ID: 26350955
[TBL] [Abstract][Full Text] [Related]
11. Systematic and MRI-Cognitive Targeted Transperineal Prostate Biopsy Accuracy in Detecting Clinically Significant Prostate Cancer after Previous Negative Biopsy and Persisting Suspicion of Malignancy.
Vėželis A; Platkevičius G; Kinčius M; Gumbys L; Naruševičiūtė I; Briedienė R; Petroška D; Ulys A; Jankevičius F
Medicina (Kaunas); 2021 Jan; 57(1):. PubMed ID: 33435132
[No Abstract] [Full Text] [Related]
12. A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection.
Hendriks RJ; van der Leest MMG; Dijkstra S; Barentsz JO; Van Criekinge W; Hulsbergen-van de Kaa CA; Schalken JA; Mulders PFA; van Oort IM
Prostate; 2017 Oct; 77(14):1401-1407. PubMed ID: 28853167
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer gene 3 and multiparametric magnetic resonance can reduce unnecessary biopsies: decision curve analysis to evaluate predictive models.
Busetto GM; De Berardinis E; Sciarra A; Panebianco V; Giovannone R; Rosato S; D'Errigo P; Di Silverio F; Gentile V; Salciccia S
Urology; 2013 Dec; 82(6):1355-60. PubMed ID: 24080222
[TBL] [Abstract][Full Text] [Related]
14. Risk Stratification by Urinary Prostate Cancer Gene 3 Testing Before Magnetic Resonance Imaging-Ultrasound Fusion-targeted Prostate Biopsy Among Men With No History of Biopsy.
Fenstermaker M; Mendhiratta N; Bjurlin MA; Meng X; Rosenkrantz AB; Huang R; Deng FM; Zhou M; Huang WC; Lepor H; Taneja SS
Urology; 2017 Jan; 99():174-179. PubMed ID: 27562202
[TBL] [Abstract][Full Text] [Related]
15. Histopathological to multiparametric MRI spatial mapping of extended systematic sextant and MR/TRUS-fusion-targeted biopsy of the prostate.
Bonekamp D; Schelb P; Wiesenfarth M; Kuder TA; Deister F; Stenzinger A; Nyarangi-Dix J; Röthke M; Hohenfellner M; Schlemmer HP; Radtke JP
Eur Radiol; 2019 Apr; 29(4):1820-1830. PubMed ID: 30327861
[TBL] [Abstract][Full Text] [Related]
16. Clinical Utility of Multiparametric Magnetic Resonance Imaging as the First-line Tool for Men with High Clinical Suspicion of Prostate Cancer.
Panebianco V; Valerio MC; Giuliani A; Pecoraro M; Ceravolo I; Barchetti G; Catalano C; Padhani AR
Eur Urol Oncol; 2018 Aug; 1(3):208-214. PubMed ID: 31102623
[TBL] [Abstract][Full Text] [Related]
17. Reduced Core Targeted (RCT) biopsy: Combining multiparametric magnetic resonance imaging - transrectal ultrasound fusion targeted biopsy with laterally-directed sextant biopsies - An alternative template for prostate fusion biopsy.
Aminsharifi A; Gupta RT; Tsivian E; Sekar S; Sze C; Polascik TJ
Eur J Radiol; 2019 Jan; 110():7-13. PubMed ID: 30599876
[TBL] [Abstract][Full Text] [Related]
18. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies.
Pokorny MR; de Rooij M; Duncan E; Schröder FH; Parkinson R; Barentsz JO; Thompson LC
Eur Urol; 2014 Jul; 66(1):22-9. PubMed ID: 24666839
[TBL] [Abstract][Full Text] [Related]
19. Avoiding Unnecessary Magnetic Resonance Imaging (MRI) and Biopsies: Negative and Positive Predictive Value of MRI According to Prostate-specific Antigen Density, 4Kscore and Risk Calculators.
Falagario UG; Martini A; Wajswol E; Treacy PJ; Ratnani P; Jambor I; Anastos H; Lewis S; Haines K; Cormio L; Carrieri G; Rastinehad AR; Wiklund P; Tewari A
Eur Urol Oncol; 2020 Oct; 3(5):700-704. PubMed ID: 31548130
[TBL] [Abstract][Full Text] [Related]
20. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
